New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:34 EDTIMMUImmunomedics announces IMMU-130 results
Immunomedics reported 10 of 14 patients with metastatic colorectal cancer responded to IMMU-130, the company's antibody-drug conjugate comprises an anti-CEACAM5 antibody and SN-38, the active metabolite of irinotecan. The 14 CT-assessable patients had a median of 4.5 prior therapies. Median time to progression for all 14 patients was at least 15.0 weeks, with 1 patient showing an 84% tumor shrinkage and an ongoing duration of partial response of more than 7 months. This patient continues to receive treatment and has received a total of 42 doses of the ADC thus far. However, to date, retreated patients have not shown an immune response to the ADC. The frequent dosing of IMMU-130 appears to be well tolerated by patients, with transient and reversible neutropenia, and manageable diarrhea the major side effects, which were mild and irregular. The company said, "In addition to CRC, CEACAM5 expression is also elevated in breast and lung cancers, as well as other tumors, making them potential targets for IMMU-130, which has shown in this trial to have a high therapeutic index."
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:50 EDTIMMUImmunomedics reports preliminary results from pretargeted imaging study
Subscribe for More Information
December 12, 2014
08:33 EDTIMMUImmunomedics ADC continues to produce 30% PR rate, 70% CBR
Subscribe for More Information
December 10, 2014
07:46 EDTIMMUOppenheimer to hold a conference
25th Annual Healthcare Conference is being held in New York on December 10-11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use